Response of Subcutaneous Xenografts of Endometrial Cancer in Nude Mice to Inhibitors of Phosphatidylinositol 3-Kinase/Akt and Mitogen-Activated Protein Kinase (MAPK) Pathways: An Effective Therapeutic Strategy for Endometrial Cancer

Ruixia Guo^*, Xinyan Wang, Ruifang Zhang, Huirong Shi, Yuhuan Qiao, Wenjing Yun, Xin Ge, Yan Lin, Jia Lei

Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

DOI: 10.4236/jct.2015.612118                

Abstract

Objective: This study was designed to explore whether inhibition of the extracellular-regulated kinase (ERK) and phosphatidylinositol-3-kinase (PI3K) signaling pathways can inhibit the growth of xenografts of endometrial cancer cell lines with different estrogen receptors (ER) profiles in vivo and to provide preliminary laboratory basis for the probability of endometrial adenocarcinoma treatment with blockage of the two pathways, especially to endometrial cancer with low ER status. Methods: Human endometrial cancer Ishikawa bearing ER and HEC-1Awith low ER status cells were subcutaneously injected into BALB/c nude mice to establish endometrial cancer xenograft tumor models. The effects of PI3K/Akt inhibitor LY294002, MAPK/ERK1/2 inhibitor PD-98059 and their combinations on the growth of the xenograft tumors and apoptotic state of Ishikawa and HEC-1Acells were tested in vivo using the inhibitory rate, the terminal deoxynucleotidyl transferase-mediated nick-end labeling assay, H/E-stain. Western blot analysis was used to detect the alterations of activated ERK (P-ERK) and AKT (P-AKT) during this process. Results: LY294002, a PI3K/Akt pathway inhibitor, induced significant suppression in the growth of both Ishikawa and HEC-1Acell xenograft tumors, concomitant with increased apoptosis in xenografts as evidenced by TUNEL. A similar effect was also observed when the MAPK/ERK1/2 signaling pathway was inhibited by PD98059. Concurrent inhibition of the PI3K/Akt and MAPK/ERK1/2 pathways showed enhanced anti-tumor effects in vivo as indicated by increased apoptosis. At the same time, the levels of P-ERK and P-AKT in both xenograft tumors decreased, and their levels in combination group was the lowest. Conclusions: PD98059, LY294002 and their combinations showed remarkable inhibitory effects on xenograft tumors of endometrial carcinoma cell lines with different expression status of ER in vivo through blockage of PI3K/Akt and MAPK/ERK1/2 signaling pathways. This suggests that targeting these pathways may be an effective therapeutic strategy against endometrial carcinomas, especially for ER-negative cancers which show poor response to endocrinal therapy.

Keywords

Extracellular-Regulated Kinase (ERK), Proto-Oncogene Proteins, Akt, ERK Pathway Inhibitor, PD98059, Phosphatidylinositol-3-Kinase Pathway Inhibitor, LY294002, Endometrial Cancer Cell, Estrogen Receptor

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Guo, R.X., Wei, L.H., Wang, J.L., et al. (2004) [Activation of Phosphatidylinositol 3-Kinase-Protein Kinase B(PI3K-PKB) Induced by 17β-Estradiol in Endometrial Carcinoma Cell (Ishikawa)]. Chinese Journal of Obstetrics and Gynecology, 39, 469-473. (In Chinese)
[2]	Guo, R.X., Wei, L.H. and Wang, J.L. (2005) [Activation of Phosphatidylinositol 3-Kinase-Proteinkinase B(PI-3K-PKB) Induced by 17β-Estradiol in Endometrial Carcinoma Cell HEC-1A)]. Progress in Obstetrics and Gynecology, 14, 270-273. (In Chinese)
[3]	Guo, R.X., Wei, L.H., Tu, Z., et al. (2006) 17 β-Estradiol Activates PI3K/Akt Signaling Pathway by Estrogen Receptor (ER)-Dependent and ER-Independent Mechanisms in Endometrial Cancer Cells. The Journal of Steroid Biochemistry and Molecular Biology, 99, 9-18. http://dx.doi.org/10.1016/j.jsbmb.2005.11.013
[4]	Huang, S.S., Guo, R.X. and Qiao, Y.H. (2009) [Effect of 17β-Estradiol on Proliferation and Expressions of P21ras and p-Erk in Endometrial Carcinoma Cells]. Progress in Obstetrics and Gynecology, 18, 17-21. (In Chinese)
[5]	Guo, R.X., Wei, L.H., Qiao, Y.H., et al. (2006) Blockage of PI3K/PKB/P27kip1 Signaling Pathway Can Antagonize 17β-Estradiol Induced Ishikawa Proliferation and Cell Cycle Progression. Chinese Medical Journal, 119, 242-245
[6]	Kohno, M. and Pouyssegur, J. (2006) Targeting the ERK Signaling Pathway in Cancer Therapy. Annals of Medicine, 38, 200-211. http://dx.doi.org/10.1080/07853890600551037
[7]	Hilger, R.A., Scheulen, M.E. and Strumberg, D. (2002) The Ras-Raf-MEK-ERK Pathway in the Treatment of Cancer. Onkologie, 25, 511-518. http://dx.doi.org/10.1159/000068621
[8]	Krasilnikov, M.A. (2000) Phosphatidylinositol-3 Kinase Dependent Pathways: The Role in Control of Cell Growth, Survival, and Malignant Transformation. Biochemistry, 65, 59-67.
[9]	Guo, R.X., Guo, H.M., Yuan, Z.F., et al. (2009) [The Expressions of G Protein-Coupled Receptor 30 and Phosphorylated AKT in Endometrial Adenocarcinoma]. Progress in Obstetrics and Gynecology, 18, 881-884. (In Chinese)
[10]	Qiao, Y.H., Niu, Q., Guo, R.X., et al. (2009) [The Clinicopathologic Significance of P21Ras and P-ERK Expression in Endometrial Carcinoma]. Chinese Journal of Clinical Obstetrics and Gynecology, 10, 277-280. (In Chinese)
[11]	Shaw, R.J. and Cantley, L.C. (2006) Ras, PI(3)K and mTOR Signalling Controls Tumour Cell Growth. Nature, 441, 424-430. http://dx.doi.org/10.1038/nature04869
[12]	Vivanco, I. and Sawyers, C.L. (2002) The Phosphatidylinositol 3-Kinase AKT Pathway in Human Cancer. Nature Reviews Cancer, 2, 489-501. http://dx.doi.org/10.1038/nrc839
[13]	Sehulze, A., Nieke, B., Wame, P.H., et al. (2004) The Transeriptional Response to Raf Activation Is Almost Completely Dependent on Mitogen-Activated Protein Kinase Activity And Shows a Major Autocrine Component. Molecular Biology of the Cell, 15, 3450-3463. http://dx.doi.org/10.1091/mbc.E03-11-0807
[14]	Guo, R.X., Qiao, Y.H. and Wei, L.H. 2007 [Effect of Phosphatidylinositol-3 Kinase Inhibitor on 17β-Estradiol-Induced Proliferation and Apoptosis in Ishikawa and HEC-1A Cells]. Journal of Zhengzhou University (Medical Sciences), 42, 322-326. (In Chinese)
[15]	Zhao, D., Li, X.-P., Wei, L.-H., et al. (2006) Stromal Cell-Derived Factor 1α Stimulates Human Endometrial Carcinoma Cell Growth through the Activation of Both Extracellular Signal-Regulated Kinase 1/2 and Akt. Gynecologic Oncology, 103, 932-937. http://dx.doi.org/10.1016/j.ygyno.2006.05.045
[16]	Guo, R.X., Wang, J.L., Zhao, D., et al. (2005) [Expressions of Estrogen Receptor α and β in Endometrial Carcinoma Cell Lines, Ishikawa and HEC-1A]. Chinese Journal of Clinical Obstetrics and Gynecology, 6, 272-274. (In Chinese)
[17]	Yaginuma, Y., Yamashita, T., Ishiva, T., et al. (2000) Abnormal Structure and Expression of PTEN/MMAC1 Gene in Human Uterine Cancers. Molecular Carcinogenesis, 2, 110-116. http://dx.doi.org/10.1002/(SICI)1098-2744(200002)27:2<110::AID-MC6>3.0.CO;2-E
[18]	Guo, R.X., Wei, L.H., Zhao, D., et al. (2006) [Effects of ICI182780 (Faslodex) on Proliferation and Apoptosis Induced by 17β-Estradiol in Endometrial Carcinoma Cells]. Beijing Da Xue Xue Bao, 38, 470-474. (In Chinese)
[19]	Amant, F., Moerman, P., Neven, P., et al. (2005) Endometrial Cancer. The Lancet, 366, 491-505. http://dx.doi.org/10.1016/S0140-6736(05)67063-8
[20]	Cantley, L.C. (2002) The Phosphoinositide 3-Kinase Pathway. Science, 296, 1655-1657. http://dx.doi.org/10.1126/science.296.5573.1655
[21]	Cantley, L.C. and Neel, B.G. (1999) New Insight into Tumor Suppression: PTEN Suppresses Tumor Formation by Restraining the Phosphoinositide 3-Kinase/AKT Pathway. Proceedings of the National Academy of Sciences of the United States of America, 96, 4240-4245. http://dx.doi.org/10.1073/pnas.96.8.4240
[22]	Steelman, L.S., Pohnert, S.C., Shelton, J.G., et al. (2004) JAK/STAT, Raf/MEK/ ERK, PI3K/Akt and BCR-ABL in Cell Cycle Progression and Leukemogenesis. Leukemia, 18, 189-218. http://dx.doi.org/10.1038/sj.leu.2403241
[23]	Lee, E.R., Kim, J.Y., Kang, Y.J., et al. (2006) Interplay between PI3K/Akt and MAPK Signaling Pathways in DNA-Damaging Drug-Induced Apoptosis. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, 1763, 958-968. http://dx.doi.org/10.1016/j.bbamcr.2006.06.006